Allergol Int: 日本青少年中,HLA-DPB1与日本柳杉花粉病和致敏作用的关系

2017-05-14 AlexYang MedSci原创

过敏性鼻炎(AR)是一种多样化的障碍疾病并且能够显著的影响日常活动、工作效率、睡眠、学习以及生活质量。日本柳杉(JC)花粉是日本最普遍的AR的过敏原。由JC花粉引起的AR被认为是一种多因子的遗传性疾病,且有环境和遗传因素共同导致的。最近,有研究人员就人类白细胞抗原-PDB1(HLA-DPB1)与JC花粉病和致敏性的关系进行了研究。研究包含了2013年到2015年的544名来自日本筑波大学的学生,并

过敏性鼻炎(AR)是一种多样化的障碍疾病并且能够显著的影响日常活动、工作效率、睡眠、学习以及生活质量。日本柳杉(JC)花粉是日本最普遍的AR的过敏原。由JC花粉引起的AR被认为是一种多因子的遗传性疾病,且有环境和遗传因素共同导致的。最近,有研究人员就人类白细胞抗原-PDB1(HLA-DPB1)与JC花粉病和致敏性的关系进行了研究。研究包含了2013年到2015年的544名来自日本筑波大学的学生,并利用PCR-SSOP技术来确定每一位个体的HLA-DPB1等位基因特点。同时,研究利用逻辑回归分析检验了JC相关的表型与HLA-DPB1的等位基因/氨基酸多态性的关系。

研究发现,HLA-DPB1*02等位基因与JC致敏性/花粉病显著相关(q<0.05)。更多的是,HLA-DPB1*02:01 和 HLA-DPB1*02:02具有JC致敏性/花粉病保护性倾向,并且HLA-DPB1*05:01对致敏性具有易感倾向(P<0.05)。在氨基酸多态性分析中,在69位置的谷氨酸、在84-87位的甘氨酸-甘氨酸-脯氨酸-甲硫氨酸、在170位的苏氨酸以及在205位的甲硫氨酸对JC致敏性表现除了保护性倾向(P<0.05)。69位的氨基酸和84-87位的氨基酸分别定位到 HLA-DPβ1的结合口袋5和1。最后,研究人员指出,氨基酸在 HLA-DPβ1的过敏原结合口袋的改变很可能影响到了JC花粉过敏肽的花粉并/致敏性,并且可以决定每个暴露于JC花粉个体的花粉病风险。

原始出处:

Morii W, Sakai A, Ninomiya T et al. Association of Japanese cedar pollinosis and sensitization with HLA-DPB1 in the Japanese adolescent. Allergol Int. 28 April 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=200892, encodeId=09652008920f, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 21 14:05:41 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199193, encodeId=b4b919919354, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed May 17 11:57:50 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294321, encodeId=bb1f129432105, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328942, encodeId=fdd91328942e8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396405, encodeId=4fe513964051e, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502025, encodeId=0be2150202569, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=)]
    2017-05-21 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=200892, encodeId=09652008920f, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 21 14:05:41 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199193, encodeId=b4b919919354, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed May 17 11:57:50 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294321, encodeId=bb1f129432105, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328942, encodeId=fdd91328942e8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396405, encodeId=4fe513964051e, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502025, encodeId=0be2150202569, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=)]
    2017-05-17 laoli

    学习了,谢谢分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=200892, encodeId=09652008920f, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 21 14:05:41 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199193, encodeId=b4b919919354, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed May 17 11:57:50 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294321, encodeId=bb1f129432105, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328942, encodeId=fdd91328942e8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396405, encodeId=4fe513964051e, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502025, encodeId=0be2150202569, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=200892, encodeId=09652008920f, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 21 14:05:41 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199193, encodeId=b4b919919354, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed May 17 11:57:50 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294321, encodeId=bb1f129432105, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328942, encodeId=fdd91328942e8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396405, encodeId=4fe513964051e, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502025, encodeId=0be2150202569, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=)]
    2017-05-16 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=200892, encodeId=09652008920f, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 21 14:05:41 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199193, encodeId=b4b919919354, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed May 17 11:57:50 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294321, encodeId=bb1f129432105, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328942, encodeId=fdd91328942e8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396405, encodeId=4fe513964051e, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502025, encodeId=0be2150202569, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=200892, encodeId=09652008920f, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun May 21 14:05:41 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199193, encodeId=b4b919919354, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed May 17 11:57:50 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294321, encodeId=bb1f129432105, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328942, encodeId=fdd91328942e8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396405, encodeId=4fe513964051e, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502025, encodeId=0be2150202569, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue May 16 02:38:00 CST 2017, time=2017-05-16, status=1, ipAttribution=)]
    2017-05-16 marongnuan

相关资讯

Int Immunopharmacol:1,25-二羟维生素D3在卵清蛋白诱导的过敏性鼻炎模型中的效应

IL-17产生的Th17细胞在过敏性气道疾病中起着重要的作用,但是人们对它们的局部表达和在过敏性鼻炎(AR)中的调控并没有很好的理解。最近,有研究调查了1,25-二羟维生素D3(1,25-(OH)2D3)对T-bet表达、Th1 细胞, Th2 细胞, Th17 细胞 和 IL-33阳性上皮细胞在AR中影响。C57BL/6小鼠是鼻敏感型的并用卵清蛋白进行挑战接触,并且向AR小鼠中进行1,25-(O

Oncotarget:白细胞介素-17中和反应是如何抑制过敏性鼻炎症状的?

过敏性鼻炎一直以来被认为主要跟Th2细胞活动有关,而与Th1细胞的关系较少。近年来,关于Th17和调节性T细胞的发现,致使1/Th2平衡范式更为复杂,也扩大了我们对过敏性鼻炎发病机制的理解。IL-17,一个由Th17产生的关键细胞因子,被认为在哮喘中诱导过敏原特异性Th2细胞激活,嗜酸性粒细胞和嗜中性粒细胞的积累,以及血清免疫球蛋白E的产生。所有这些特征也许在过敏性鼻炎中也起到重要作用。据我们所知

中医中药能不能治疗过敏性鼻炎

作为西医医生,常常听到很多过敏性鼻炎患者在咨询:中医中药可以治疗过敏性鼻炎吗?让我们来具体分析一下。中医理论体系中的过敏性鼻炎中医理论将过敏性鼻炎称为“鼻鼽”,并根据中医的辨证体系将其具体分为肺气虚寒型、脾气虚弱型、肾阳不足型、肺经伏热型和邪伏少阳型等症型,又根据不同症型进行具体治疗,包括内治法(中药和中成药等)和外治法(中药熏洗、塞鼻和针灸等),可谓是个体化治疗的典范。但是中医治疗该病缺乏宏观和

“脱敏疫苗”治疗过敏性鼻炎,对身体是否有害

很多人对过敏性鼻炎的脱敏治疗方式有疑问,这些疑问中有两个比较典型,其一是,进行脱敏治疗的疫苗对身体是否有害?其二是,脱敏治疗过程中产生的新抗体对身体是否有副作用?何为“脱敏治疗”先来了解一下脱敏治疗,就拿过敏原尘螨来说吧。用于进行脱敏治疗的尘螨是在严格流程下生产出来的疫苗,其实质是尘螨的浸出液,就是把尘螨放到某种溶液里进行浸泡,待溶液中某些蛋白达到一定浓度时,便收集该溶液,按标准流程生产出过敏原疫

过敏免疫舌下含片Acarizax获欧盟批准 用于青少年过敏性鼻炎

过敏免疫治疗领域的全球领导者ALK-Abello公司近日宣布其屋尘螨(house dust mite,HDM)过敏免疫舌下含片(SLIT)Acarizax获12个欧洲国家批准扩大适用人群,纳入12-17岁青少年患者,治疗由屋尘螨诱发的过敏性鼻炎。此次扩大批准,是基于全球性Acarizax临床开发项目在日本、北美开展的临床研究数据。研究结果证实,Acarizax用于12-17岁青少年患者治疗由屋尘螨

预防儿童过敏性鼻炎,从日常生活开始

小儿过敏性鼻炎,即小儿变应性鼻炎,是变态反应性鼻炎的简称。变应性鼻炎是儿童极为常见的一种慢性鼻黏膜充血的疾病,主要的临床症状有鼻痒、打喷嚏、流清鼻涕、鼻塞、鼻涕倒流、夜间突然咳嗽。和感冒不同的是,变应性鼻炎一般是在气候改变、早上起床,或吸入外界过敏性抗原如空气中的粉尘时发作,一天之中可能间歇出现。预防性治疗1.避免变应原和刺激物:戴口罩可以防止文中所提到的柳絮或粉尘飞入鼻孔,且避开风大柳絮多的时间